Reprint

Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer

Edited by
June 2022
258 pages
  • ISBN978-3-0365-4383-3 (Hardback)
  • ISBN978-3-0365-4384-0 (PDF)

This book is a reprint of the Special Issue Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

This book—entitled “Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer”—was edited as a Special Issue of Biomedicines, focusing on basic research such as genomics, epigenomics, and proteomics, as well as clinical research in the field of gynecologic oncology.

The number of patients with gynecological cancer has been increasing worldwide due to its high lethality and lack of early detection tools and effective therapeutic interventions. In this regard, basic research on its pathophysiology and novel molecular targeting intervention is required to improve the prognosis of gynecologic cancer.

This book contains 13 papers, including 8 original research papers and 5 reviews focusing on the basic research of gynecologic oncology. The reader can learn about state-of-the-art research and obtain extensive knowledge of the current advances in the field of gynecologic oncology. It is my hope that this book contributes towards the progress of gynecologic oncology.

Format
  • Hardback
License
© by the authors
Keywords
nucleus accumbens-associated protein 1 (NAC1); BEN (BANP, E5R and NAC1) domain; sequence-specific DNA-binding protein; solution NMR structure; isothermal titration calorimetry (ITC); human cytomegalovirus; ovarian cancer; cancer progression; inflammation; immunosuppression; endometrial carcinoma; immune micro-environment; immune checkpoints inhibitors; microsatellite instability; mismatch repair deficiency; platelet-activating factor acetylhydrolase (PAF-AH; PLA2G7); BRCA1 mutant ovarian cancer; Wnt signaling; pGSK3β; β-catenin; prognosis; vulvar melanoma; vaginal melanoma; targeted therapy; gynecological cancer; melanoma treatment; gene ontology; epithelial ovarian cancers; borderline ovarian tumors; differentially expressed genes; aryl hydrocarbon receptor; epithelial–mesenchymal transition; integrative analysis; testin; p16 protein; cervical cancer; cervical neoplasia; immunohistochemistry; chimeric antigen receptor; ovarian cancer; CD44; adoptive immunotherapy; NK cells; epithelial ovarian cancer; DNA damage response; somatic mutation; clear cell carcinoma; endometrioid endometrial cancer; DNA mismatch repair (MMR); MMR deficient (dMMR); long-term survival; exosome; miRNA; biomarkers; epithelial ovarian cancer; liquid biopsy; interventional radiotherapy; vaginal-cuff brachytherapy; HDR brachytherapy; in vivo dosimetry; endometrial cancer; biological planning; epithelial ovarian cancer; drug repurposing; non-coding RNAs; nanocarriers; anti-angiogenic therapy; n/a